Loading…
ImmunityBio, Inc. is projected to rise to $8.51 by 2027, a +14% move from its current price of $7.45. IBRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $7.18 | $7.45 | $7.74 | +0.01% |
| Aug 2 | $7.07 | $7.45 | $7.86 | +0.02% |
| Aug 3 | $6.98 | $7.45 | $7.95 | +0.03% |
| Aug 4 | $6.92 | $7.45 | $8.03 | +0.04% |
| Aug 5 | $6.86 | $7.45 | $8.11 | +0.05% |
| Aug 6 | $6.80 | $7.45 | $8.17 | +0.06% |
| Aug 7 | $6.75 | $7.46 | $8.23 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.75 | $7.46 | $8.23 | +0.07% |
| Week 2 | $6.49 | $7.46 | $8.58 | +0.15% |
| Week 3 | $6.29 | $7.47 | $8.86 | +0.22% |
| Week 4 | $6.13 | $7.47 | $9.11 | +0.29% |
| Week 5 | $5.99 | $7.48 | $9.33 | +0.37% |
| Week 6 | $5.87 | $7.48 | $9.54 | +0.44% |
| Week 7 | $5.76 | $7.49 | $9.73 | +0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Its platforms for the development of biologic products and product candidates include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. ImmunityBio’s lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd.
It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute.
ImmunityBio, Inc. is based in San Diego, California.
ImmunityBio, Inc. (IBRX) operates in the Healthcare sector and trades as a biotechnology-focused equity. The stock is currently priced at $7.10 per share with a market capitalization of $7.44B and a competitive standing of rank 1014 by market cap.
The current price and market position frame a longer horizon that projects upside through the 2026–2050 forecast horizon. The 2026 baseline shows an average price of $7.10, with a path toward higher values in later years, including a 2029 average of $11.49 and a 2030 average of $13.33, culminating in a 2050 average of $54.50. Across these years, the forecast implies rising ROIs from 61.9% in 2029 to 87.7% in 2030 and up to 667.5% by 2050, with bullish sentiment emerging in the later years.
A major floor 28.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 26.7% above — a clean break opens room to run.
A major ceiling 41.2% above — clearing it would confirm fresh momentum.
Key IBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.07 | Buy | $7.19 | Buy |
| MA 10 | $7.35 | Buy | $7.35 | Buy |
| MA 20 | $7.87 | Sell | $7.58 | Sell |
| MA 50 | $7.69 | Sell | $7.69 | Sell |
| MA 100 | $7.73 | Sell | $7.36 | Buy |
| MA 200 | $5.89 | Buy | $6.37 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.21 | Neutral |
| Stoch RSI (14) | 71.39 | Neutral |
| CCI (20) | -46.27 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -5.46 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.74 | Sell |
| Ultimate (7,14,28) | 37.67 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 6.89 | Buy |
| ADX (14) | 16.11 | Neutral |
| ATR (14) | 0.27 | Info |
The 30-day technical picture for IBRX is NEUTRAL. The RSI(14) is 40, and the price action sits between the SMA50 of $7.79 and the SMA200 of $5.78 as near-term guideposts.
Support is identified at $6.72 and resistance at $9.44, with the 30-day price range trading from $5.56 to $9.07. Annualized volatility runs around 70%, underscoring notable but contained near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.02 | $7.45 | $9.59 | 0% | Neutral | |
| $6.55 | $8.51 | $11.80 | +14% | Neutral | |
| $6.64 | $8.98 | $13.08 | +20% | Bullish | |
| $8.58 | $12.00 | $18.15 | +61% | Bullish | |
| $9.74 | $14.02 | $21.89 | +88% | Bullish | |
| $9.15 | $13.55 | $21.74 | +82% | Bullish | |
| $9.35 | $14.20 | $23.35 | +91% | Bullish | |
| $9.39 | $14.61 | $24.55 | +96% | Bullish | |
| $9.86 | $15.72 | $26.94 | +111% | Bullish | |
| $11.82 | $19.25 | $33.62 | +158% | Bullish | |
| $13.51 | $24.44 | $46.07 | +228% | Bullish | |
| $26.28 | $57.47 | $120.88 | +671% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.02 | $7.45 | $8.70 | +0.00% |
| August 2026 | $6.13 | $7.25 | $8.82 | -2.70% |
| September 2026 | $6.29 | $7.52 | $9.32 | +3.75% |
| October 2026 | $6.39 | $7.71 | $9.69 | +2.57% |
| November 2026 | $6.16 | $7.50 | $9.52 | -2.84% |
| December 2026 | $6.10 | $7.47 | $9.59 | -0.31% |
Click any year to see its month-by-month IBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IBRX to range from $2.02 to $9.59 through 2026. The $7.45 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IBRX price prediction for 2027 points to an average of $8.51 (low $6.55, high $11.80) — a potential gain of +14% on today's $7.45. A consolidation phase looks the most probable path here.
In 2028, IBRX is projected to trade between $6.64 and $13.08, averaging $8.98 — a potential gain of +20% from today's $7.45. That is up +6% on the projected 2027 average. Momentum favours further upside here.
ImmunityBio, Inc.'s 2029 outlook centres on $12.00, within a $8.58 to $18.15 range. That is up +34% on the projected 2028 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IBRX could reach as high as $21.89, with a base case around $14.02 and support toward $9.74 — roughly +88% from $7.45. Momentum favours further upside here.
Expect IBRX to range from $9.15 to $21.74 through 2031. The $13.55 average target implies a +82% move from current prices. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The IBRX price prediction for 2032 points to an average of $14.20 (low $9.35, high $23.35) — a potential gain of +91% on today's $7.45. Momentum favours further upside here.
In 2033, IBRX is projected to trade between $9.39 and $24.55, averaging $14.61 — a potential gain of +96% from today's $7.45. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
ImmunityBio, Inc.'s 2034 outlook centres on $15.72, within a $9.86 to $26.94 range. That is up +8% on the projected 2033 average. That marks a +111% change versus current levels. Momentum favours further upside here.
By 2035, IBRX could reach as high as $33.62, with a base case around $19.25 and support toward $11.82 — roughly +158% from $7.45. Buyers look set to stay in control over this stretch.
Expect IBRX to range from $13.51 to $46.07 through 2040. The $24.44 average target implies a +228% move from current prices. That is up +27% on the projected 2035 average. Momentum favours further upside here.
The IBRX price prediction for 2050 points to an average of $57.47 (low $26.28, high $120.88) — a potential gain of +671% on today's $7.45. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBRX today (≈ 134.228188 IBRX) could be worth
$7,714.08
+$6,714.08 (+671%) by 2050 · US Dollar
Based on the average projected IBRX price of $57.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBRXwould be worth at today's price.
$1,000 invested in IBRX on Jul 30, 2025 (≈ 390.625009 IBRX) would be worth
$2,910.16
+$1,910.16 (+191.0%) today · 2.91× · US Dollar
Based on a IBRX entry price of $2.56 vs. today's $7.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.4 | $1,006.76 | +0.7% |
| 1 month ago | $8.76 | $850.94 | -14.9% |
| 3 months ago | $7.11 | $1,047.82 | +4.8% |
| 6 months ago | $6.25 | $1,192 | +19.2% |
| 1 year ago | $2.56 | $2,910.16 | +191.0% |
| All time (5.0y) ago | $11.2 | $665.18 | -33.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBRX forecast.
Our base-case forecast reaches $15.00 around 2034.
Implied market cap at $15.00: $15.71B
The multi-year forecast points to a bullish trajectory beyond 2026, with notable milestones in 2029, 2030, 2040, and 2050. The 2029 forecast shows an average price of $11.49 with an ROI of 61.9 and a bullish sentiment; 2030 shows an average of $13.33 with an ROI of 87.7 and bullish sentiment. By 2040, the average price is projected to $22.96 with an ROI of 223.4, and by 2050 the average rises to $54.50 with an ROI of 667.5, all under bullish sentiment.
Specific year-by-year snapshots include 2026 min $2.02, avg $7.10, max $9.21 (ROI 0; sentiment NEUTRAL) and 2027–2035 gradually higher averages and ROIs, culminating in the 2050 forecast. These figures are estimates, not guarantees, and are subject to market and sector-specific risks inherent in biotechnology equities.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $13.33, an ROI of 87.7, and bullish sentiment.
The forecast suggests bullish sentiment from 2029 onward, with the average price rising to $13.33 in 2030 and to $54.50 in 2050, but these are estimates and not guarantees.
Yes. The 2040 forecast lists an average price of $22.96, which surpasses $20, indicating potential above-$20 levels in the forecast horizon.
The near-term view is NEUTRAL, with RSI(14) at 40, SMA50 at $7.79, SMA200 at $5.78, support at $6.72, resistance at $9.44, and a 30-day range of $5.56 to $9.07.
Current price is $7.10 and market cap is $7.44B; the stock is ranked 1014.
ImmunityBio, Inc. Community Discussion
0Share your ImmunityBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.